Telix Pharmaceuticals Limited
Darren Charlton Smith (Group Chief Financial Officer) buys TLX shares
About this filing
Telix Pharmaceuticals Limited (TLX) filed Form 4 (insider transaction) with the SEC on Sep 14, 2026. Form 4 reports a company insider’s trades in the company’s shares.
Key facts
- Insider
- Darren Charlton Smith · Group Chief Financial Officer
| Date | Transaction | Shares | Price | Value | Held after | Ownership |
|---|---|---|---|---|---|---|
| Sep 7, 2026 | P · purchaseFootnotes F1, F2 | +2,071 | $9.66 | $19,997.58 | 13,992 | Direct |
Footnotes
- F1 Represents shares purchased by the Reporting Person under the Employee Share Purchase Plan section of the Issuer's Equity Incentive Plan ("AU ESPP"), which shares were allocated on September 7, 2026, based on the Reporting Person's contributions to the AU ESPP from January 1, 2026 - June 30, 2026.
- F2 Purchase price is recorded in Australian Dollars.
More TLX filings
- 6-K
Filed Oct 29, 2026
- 6-K
Filed Oct 20, 2026
- 6-K
Filed Sep 29, 2026
- 6-K
Filed Sep 21, 2026
- 6-K
Filed Sep 14, 2026
- 6-K
Filed Sep 1, 2026
Not investment advice. Summaries can contain errors; the SEC filing is the official record.